ArticleResearch and practice in thrombosis and haemostasis2022
Evaluation of the Khorana score for prediction of venous thromboembolism in patients with multiple myeloma.
Article in Research and practice in thrombosis and haemostasis, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 2 syntheses or guidelines pooled it, 27 citations in OpenAlex.
- Pooled it
- Mitigating the risk of venous thromboembolism in patients with multiple myeloma receiving immunomodulatory-based therapy.Hematology. American Society of Hematology. Education Program · 2022Pooled it
- Geriatric nutritional risk index for the prediction of venous thrombotic events in multiple myeloma.International journal of clinical oncology · 2026Article
- External validation of established clinical risk scores for cancer-associated venous thromboembolism in a Brazilian registry.Journal of thrombosis and thrombolysis · 2026Article
- Study on Risk Factors and Treatment Strategies for Deep Vein Thrombosis in Patients with Multiple Myeloma.Cancer management and research · 2025Review
- Multiple myeloma: retrospective assessment of routine thromboprophylaxis and utility of thrombotic risk scores.Research and practice in thrombosis and haemostasis · 2024Article
- Review
- Incidence of and risk factors for venous thrombosis in hospitalized patients with hematologic malignancies: A single-center, prospective cohort study.Northern clinics of Istanbul · 2024Article
- Validation of venous thromboembolism predictive model in hematologic malignancies.Annals of hematology · 2023Article
- Hematologists' awareness of venous thromboembolism in multiple myeloma: a national survey in China.Annals of medicine · 2023Article
- Approach to Contemporary Risk Assessment, Prevention and Management of Thrombotic Complications in Multiple Myeloma.Cancers · 2022Review
- Thrombosis in multiple myeloma: risk stratification, antithrombotic prophylaxis, and management of acute events. A consensus-based position paper from anHaematologica · 2022Article
- Evaluation of the Khorana score for prediction of venous thromboembolism in patients with multiple myeloma.Research and practice in thrombosis and haemostasis · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 2 countries.
Funding
Abstract
backgroundGuidelines recommend thromboprophylaxis for patients with multiple myeloma (MM) at high risk for venous thromboembolism (VTE). However, the optimal risk prediction model for VTE in MM remains unclear. Khorana et al developed a VTE risk score (Khorana score) in ambulatory cancer patients receiving chemotherapy. We aimed to evaluate the predictive ability of the Khorana score in patients with MM.
methodsWe identified patients with MM within the Veterans Affairs health care system between 2006 and 2013. The Khorana score was calculated before treatment initiation. Using logistic regression, the relationship between risk group and VTE was assessed at 3 and 6 months. We tested model discrimination using the concordance statistic.
resultsIn the cohort of 2870 patients with MM, there were 1328 at low risk (0 points), 1521 at intermediate risk (1-2 points), and 21 at high risk (≥3 points) for VTE by the Khorana score. The 6-month cumulative incidence of VTE was 5.1% (95% confidence interval [CI], 4.0%-6.4%) in low risk, 3.9% (95% CI, 3.0%-5.0%) in intermediate risk, 4.8% (95% CI, 0.3%-20.2%) in high risk. The Khorana score did not strongly discriminate between patients who did and did not develop VTEs at 3 or 6 months (concordance statistic, 0.58; 95% CI, 0.54-0.63; and 0.53, 95% CI, 0.50-0.57, respectively.
conclusionsIn conclusion, in this cohort of 2870 patients with MM, the Khorana score did not predict VTE. Our study supports the need to use myeloma-specific risk models to predict VTE risk in patients with MM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.